Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Translated into:
Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Introduction to Vampine T Cefepime and Tazobactam Injection
Vampine T, offered by Lexaro Healthcare, contains a fixed-dose combination of Cefepime and Tazobactam. Cefepime is a fourth-generation cephalosporin antibiotic with a broad spectrum of activity against gram-positive and gram-negative bacteria. Tazobactam is a beta-lactamase inhibitor that protects Cefepime from degradation by bacterial enzymes, thereby extending its antibacterial efficacy.
Uses of Vampine T Cefepime and Tazobactam Injection
Vampine T is primarily prescribed for:
Treating serious infections including intra-abdominal infections, pneumonia, and urinary tract infections.
Managing infections caused by both aerobic and anaerobic bacteria that are resistant to other antibiotics.
Providing effective treatment for complicated infections in hospitalized patients.
Addressing severe infections where beta-lactamase-producing bacteria are involved.
Benefits of Vampine T Cefepime and Tazobactam Injection
Combines a broad-spectrum cephalosporin with a beta-lactamase inhibitor for enhanced antibacterial activity.
Effective against a wide range of bacterial pathogens, including those resistant to other antibiotics.
Provides comprehensive coverage for serious and complicated infections.
Administered via injection for direct systemic treatment in a hospital setting.
Offers a synergistic approach to overcoming bacterial resistance and improving clinical outcomes.
Mechanism of Action of Vampine T Cefepime and Tazobactam Injection
Cefepime works by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins (PBPs). This inhibition disrupts the cross-linking of peptidoglycan layers in the bacterial cell wall, leading to cell lysis and death.
Tazobactam is a beta-lactamase inhibitor that protects Cefepime from being inactivated by bacterial enzymes known as beta-lactamases. By inhibiting these enzymes, Tazobactam enhances the efficacy of Cefepime against beta-lactamase-producing bacteria.